CISATRACURIUM Drug Patent Profile
✉ Email this page to a colleague
When do Cisatracurium patents expire, and what generic alternatives are available?
Cisatracurium is a drug marketed by Accord Hlthcare, Caplin, Eugia Pharma, Fresenius Kabi Usa, Gland, Hainan Poly, Hengrui Pharma, Hikma, Hospira, Meitheal, Piramal, Sagent Pharms Inc, Sandoz Inc, Somerset, Zydus Pharms, and Somerset Theraps Llc. and is included in twenty-six NDAs.
The generic ingredient in CISATRACURIUM is cisatracurium besylate. There are nine drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the cisatracurium besylate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Cisatracurium
A generic version of CISATRACURIUM was approved as cisatracurium besylate by SANDOZ INC on February 3rd, 2012.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for CISATRACURIUM?
- What are the global sales for CISATRACURIUM?
- What is Average Wholesale Price for CISATRACURIUM?
Summary for CISATRACURIUM
| US Patents: | 0 |
| Applicants: | 16 |
| NDAs: | 26 |
| Drug Prices: | Drug price information for CISATRACURIUM |
| DailyMed Link: | CISATRACURIUM at DailyMed |
US Patents and Regulatory Information for CISATRACURIUM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Somerset Theraps Llc | CISATRACURIUM BESYLATE PRESERVATIVE FREE | cisatracurium besylate | INJECTABLE;INJECTION | 206791-001 | Feb 20, 2019 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Eugia Pharma | CISATRACURIUM BESYLATE PRESERVATIVE FREE | cisatracurium besylate | INJECTABLE;INJECTION | 209665-001 | Oct 27, 2020 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Zydus Pharms | CISATRACURIUM BESYLATE | cisatracurium besylate | INJECTABLE;INJECTION | 213527-001 | Sep 1, 2020 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Fresenius Kabi Usa | CISATRACURIUM BESYLATE PRESERVATIVE FREE | cisatracurium besylate | INJECTABLE;INJECTION | 203182-001 | Feb 26, 2015 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
